Genfit is a biotechnology business based in the US. Genfit shares (GNFT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.61 – an increase of 3.14% over the previous week. Genfit employs 169 staff and has a trailing 12-month revenue of around $80.5 million.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – GNFT.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Genfit stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Genfit stock price (NASDAQ: GNFT)
Use our graph to track the performance of GNFT stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Genfit price performance over time
Historical closes compared with the close of $3.64 from 2025-03-18
1 week (2025-03-13)
4.00%
1 month (2025-02-21)
-4.96%
3 months (2024-12-20)
-4.21%
6 months (2024-09-20)
-24.79%
1 year (2024-03-20)
0.00%
2 years (2023-03-20)
-10.85%
3 years (2022-03-18)
4.06
5 years (2020-03-20)
13.63
Is Genfit stock undervalued or overvalued?
Valuing Genfit stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genfit's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genfit's P/E ratio
Genfit's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Genfit shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Genfit's EBITDA
Genfit's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.9 million.
The EBITDA is a measure of a Genfit's overall financial performance and is widely used to measure a its profitability.
Genfit financials
Revenue TTM
$80.5 million
Operating margin TTM
51%
Gross profit TTM
$80.5 million
Return on assets TTM
6.51%
Return on equity TTM
25.91%
Profit margin
27.68%
Book value
$1.96
Market Capitalization
$184.3 million
TTM: trailing 12 months
Genfit share dividends
We're not expecting Genfit to pay a dividend over the next 12 months.
Genfit share price volatility
Over the last 12 months, Genfit's shares have ranged in value from as little as $3.11 up to $6.4229. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genfit's is 1.075. This would suggest that Genfit's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Genfit overview
Genfit S. A. , a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Frequently asked questions
null What percentage of Genfit is owned by institutions? Currently 0.524% of Genfit shares are held by institutions.How many people work for Genfit? Latest data suggests 169 work at Genfit.When does the fiscal year end for Genfit? Genfit's fiscal year ends in December.Where is Genfit based? Genfit's address is: Parc EurasantE, Loos, France, 59120What is Genfit's ISIN number? Genfit's international securities identification number is: US3722791098What is Genfit's CUSIP number? Genfit's Committee on Uniform Securities Identification Procedures number is: 372279109
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
